We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
Boston Scientific (BSX - Free Report) closed the most recent trading day at $92.51, moving +1.34% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.03% for the day. At the same time, the Dow lost 0.58%, and the tech-heavy Nasdaq gained 0.28%.
Shares of the medical device manufacturer have depreciated by 5.03% over the course of the past month, underperforming the Medical sector's loss of 0.01%, and the S&P 500's gain of 0.6%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on February 4, 2026. The company is expected to report EPS of $0.78, up 11.43% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $5.27 billion, showing a 15.44% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.04 per share and a revenue of $20.06 billion, signifying shifts of +21.12% and 0%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Boston Scientific holds a Zacks Rank of #2 (Buy).
From a valuation perspective, Boston Scientific is currently exchanging hands at a Forward P/E ratio of 26.43. This denotes a premium relative to the industry average Forward P/E of 20.37.
Also, we should mention that BSX has a PEG ratio of 1.62. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BSX's industry had an average PEG ratio of 1.72 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
Boston Scientific (BSX - Free Report) closed the most recent trading day at $92.51, moving +1.34% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.03% for the day. At the same time, the Dow lost 0.58%, and the tech-heavy Nasdaq gained 0.28%.
Shares of the medical device manufacturer have depreciated by 5.03% over the course of the past month, underperforming the Medical sector's loss of 0.01%, and the S&P 500's gain of 0.6%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on February 4, 2026. The company is expected to report EPS of $0.78, up 11.43% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $5.27 billion, showing a 15.44% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.04 per share and a revenue of $20.06 billion, signifying shifts of +21.12% and 0%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Boston Scientific holds a Zacks Rank of #2 (Buy).
From a valuation perspective, Boston Scientific is currently exchanging hands at a Forward P/E ratio of 26.43. This denotes a premium relative to the industry average Forward P/E of 20.37.
Also, we should mention that BSX has a PEG ratio of 1.62. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BSX's industry had an average PEG ratio of 1.72 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.